Aerie launches Ph3 trial for Roclatan eye drug in Europe

Aerie Pharmaceuticals (NSDQ:AERI) said today that it launched its European Mercury 3 late-stage trial of Roclatan in patients with open-angle glaucoma or ocular hypertension.

The eye drug is a fixed dose combination of Aerie’s Rhopressa netarsudil ophthalmic solution and a widely-used prostaglandin analogue, latanoprost. The company’s Phase III trial was designed to support regulatory approval and commercialization in Europe, Aerie said.

Get the full story at our sister site, Drug Delivery Business News.

The post Aerie launches Ph3 trial for Roclatan eye drug in Europe appeared first on MassDevice.

from MassDevice http://ift.tt/2wIHZMH